BACKGROUND: Most studies of catheter ablation for the treatment of ventricular tachycardia (VT) are relatively small observational trials. OBJECTIVE: The purpose of this study was to define the relative risk of VT recurrence in patients undergoing catheter ablation as an adjunct to medical therapy versus medical therapy alone in a pooled analysis of controlled studies. METHODS: Randomized and nonrandomized controlled trials of patients who underwent adjunctive catheter ablation of VT versus medical therapy alone were sought. MEDLINE, EMBASE, the Cochrane central register of controlled trials (CENTRAL), and Web of Science were searched from 1965 to July 2010. Supplemental searches included Internet resources, reference lists, and reports of arrhythmia experts. Three authors independently reviewed and extracted the data regarding baseline characteristics, ablation methodology, medical therapy, complications, VT recurrences, mortality, and study quality. RESULTS: Five studies were included totaling 457 participants with structural heart disease. Adjunctive catheter ablation was performed in 58% of participants, whereas 42% received medical therapy alone for VT. Complications of catheter ablation included death (1%), stroke (1%), cardiac perforation (1%), and complete heart block (1.6%). Using a random-effects model, a statistically significant 35% reduction in the number of patients with VT recurrence was noted with adjunctive catheter ablation (P<.001). There was no statistically significant difference in mortality. CONCLUSIONS: Catheter ablation as an adjunct to medical therapy reduces VT recurrences in patients with structural heart disease and has no impact on mortality.
BACKGROUND: Most studies of catheter ablation for the treatment of ventricular tachycardia (VT) are relatively small observational trials. OBJECTIVE: The purpose of this study was to define the relative risk of VT recurrence in patients undergoing catheter ablation as an adjunct to medical therapy versus medical therapy alone in a pooled analysis of controlled studies. METHODS: Randomized and nonrandomized controlled trials of patients who underwent adjunctive catheter ablation of VT versus medical therapy alone were sought. MEDLINE, EMBASE, the Cochrane central register of controlled trials (CENTRAL), and Web of Science were searched from 1965 to July 2010. Supplemental searches included Internet resources, reference lists, and reports of arrhythmia experts. Three authors independently reviewed and extracted the data regarding baseline characteristics, ablation methodology, medical therapy, complications, VT recurrences, mortality, and study quality. RESULTS: Five studies were included totaling 457 participants with structural heart disease. Adjunctive catheter ablation was performed in 58% of participants, whereas 42% received medical therapy alone for VT. Complications of catheter ablation included death (1%), stroke (1%), cardiac perforation (1%), and complete heart block (1.6%). Using a random-effects model, a statistically significant 35% reduction in the number of patients with VT recurrence was noted with adjunctive catheter ablation (P<.001). There was no statistically significant difference in mortality. CONCLUSIONS: Catheter ablation as an adjunct to medical therapy reduces VT recurrences in patients with structural heart disease and has no impact on mortality.
Authors: Andrea Natale; Antonio Raviele; Amin Al-Ahmad; Ottavio Alfieri; Etienne Aliot; Jesus Almendral; Günter Breithardt; Josep Brugada; Hugh Calkins; David Callans; Riccardo Cappato; John A Camm; Paolo Della Bella; Gerard M Guiraudon; Michel Haïssaguerre; Gerhard Hindricks; Siew Yen Ho; Karl H Kuck; Francis Marchlinski; Douglas L Packer; Eric N Prystowsky; Vivek Y Reddy; Jeremy N Ruskin; Mauricio Scanavacca; Kalyanam Shivkumar; Kyoko Soejima; William J Stevenson; Sakis Themistoclakis; Atul Verma; David Wilber Journal: J Cardiovasc Electrophysiol Date: 2010-01-15
Authors: Stefan H Hohnloser; Karl Heinz Kuck; Paul Dorian; Robin S Roberts; John R Hampton; Robert Hatala; Eric Fain; Michael Gent; Stuart J Connolly Journal: N Engl J Med Date: 2004-12-09 Impact factor: 91.245
Authors: Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip Journal: N Engl J Med Date: 2005-01-20 Impact factor: 91.245
Authors: H Calkins; A Epstein; D Packer; A M Arria; J Hummel; D M Gilligan; J Trusso; M Carlson; R Luceri; H Kopelman; D Wilber; J M Wharton; W Stevenson Journal: J Am Coll Cardiol Date: 2000-06 Impact factor: 24.094
Authors: Stuart J Connolly; Paul Dorian; Robin S Roberts; Michael Gent; Steven Bailin; Eric S Fain; Kevin Thorpe; Jean Champagne; Mario Talajic; Benoit Coutu; Gerian C Gronefeld; Stefan H Hohnloser Journal: JAMA Date: 2006-01-11 Impact factor: 56.272
Authors: Mark J Earley; Refai Showkathali; Maysaa Alzetani; Peter M Kistler; Dhiraj Gupta; Dominic J Abrams; Julie A Horrocks; Stuart J Harris; Simon C Sporton; Richard J Schilling Journal: Eur Heart J Date: 2006-04-13 Impact factor: 29.983
Authors: Sean D Pokorney; Daniel J Friedman; Hugh Calkins; David J Callans; Emile G Daoud; Paolo Della-Bella; Kevin P Jackson; Kalyanam Shivkumar; Samir Saba; John Sapp; William G Stevenson; Sana M Al-Khatib Journal: Heart Rhythm Date: 2016-04-02 Impact factor: 6.343
Authors: Prabhat Kumar; J Paul Mounsey; Anil K Gehi; Jennifer D Schwartz; Eugene H Chung Journal: J Interv Card Electrophysiol Date: 2013-04-19 Impact factor: 1.900